AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23127920 — intervention group
Group type: EXPERIMENTAL
Intervention: CIDR-G of third use (previously used twice)
Number of subjects: 319
Study 23127920 — intervention group
Group type: EXPERIMENTAL
Intervention: CIDR-G of second use (previously used once)
Number of subjects: 319
Study 21544559 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care intervention
Number of subjects: 200
Study 21544559 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 200
Study 18438876 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 58
Study 16546678 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 10
Study 16546678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 12697590 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil at 2 ng ml(‐1) (low)
Number of subjects: 60
Study 12697590 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil at 4 ng ml(‐1) (medium)
Number of subjects: 60
Study 12697590 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil at 8 ng ml(‐1) (high)
Number of subjects: 60
Study 12697590 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (high concentration group)
Number of subjects: 60
Study 12697590 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol effect site concentration
Number of subjects: 60
Study 10882619 — intervention group
Group type: EXPERIMENTAL
Intervention: IncAHI <21.5 days
Number of subjects: 70
Study 10882619 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of AHI >15.5 days
Number of subjects: 70
Study 10882619 — intervention group
Group type: COMPARATOR
Intervention: IncAHI >21.5 days
Number of subjects: 70
Study 10882619 — intervention group
Group type: COMPARATOR
Intervention: Duration of AHI <15.5 days
Number of subjects: 70
Study 8936126 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose polymer sports drink (GPSD)
Number of subjects: 25
Study 8936126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 1426295 — intervention group
Group type: EXPERIMENTAL
Intervention: Transrectal ultrasound (TRUS)
Number of subjects: 15
Study 1426295 — intervention group
Group type: COMPARATOR
Intervention: Digital rectal examination (DRE)
Number of subjects: 15
Study 2931421 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaterol inhaled (10 micrograms)
Number of subjects: 9
Study 2931421 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered with a pressurized metered-dose inhaler)
Number of subjects: 9
Study 31563302 — intervention group
Group type: EXPERIMENTAL
Intervention: DAR score categories (low, low-intermediate, high-intermediate, high)
Number of subjects: 275
Study 31563302 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group comparison
Number of subjects: 275
Study 31563302 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention duration
Number of subjects: 275
Study 29450636 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cyclophosphamide (CYC) 6 × 500 mg fortnightly
Number of subjects: 75
Study 29450636 — intervention group
Group type: COMPARATOR
Intervention: High-dose cyclophosphamide (CYC) 6 × 750 mg/m2 four-weekly
Number of subjects: 75
Study 29450636 — intervention group
Group type: COMPARATOR
Intervention: High-dose cyclophosphamide (CYC)
Number of subjects: 75
Study 29450636 — intervention group
Group type: COMPARATOR
Intervention: Low-dose cyclophosphamide (CYC)
Number of subjects: 75
Study 26826547 — intervention group
Group type: EXPERIMENTAL
Intervention: HantavaxTM (three-dose schedule at 0, 1, and 13 months)
Number of subjects: 226
Study 24792102 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.4 mm scleral tunnel incision
Number of subjects: 64
Study 24792102 — intervention group
Group type: COMPARATOR
Intervention: 2.4 mm clear corneal incision
Number of subjects: 64
Study 22283848 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate (4 g day⁻¹ for 15 days)
Number of subjects: 96
Study 22283848 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin (400 mg single dose preceded by 15 days of placebo)
Number of subjects: 96
Study 22283848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 19575740 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol 3350 (PEG), 3.45 g t.i.d. orally for 30 days
Number of subjects: 42
Study 19575740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 18036064 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 16
Study 18036064 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily insulin injections (MDI)
Number of subjects: 16
Study 18036064 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII
Number of subjects: 16
Study 18036064 — intervention group
Group type: COMPARATOR
Intervention: MDI
Number of subjects: 16
Study 16059855 — intervention group
Group type: EXPERIMENTAL
Intervention: DynEx dynamometer
Number of subjects: 100
Study 11973420 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenomedullin (0.05 microg/kg/min)
Number of subjects: 14
Study 11973420 — intervention group
Group type: COMPARATOR
Intervention: Atrial natriuretic peptide (ANP) (0.05 microg/kg/min)
Number of subjects: 14
Study 10361110 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended ATRA (5-day course before chemotherapy)
Number of subjects: 239
Study 10361110 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended ATRA
Number of subjects: 239
Study 10361110 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended ATRA in patients with WBC < 10 x 10(9)/L
Number of subjects: 239
Study 10361110 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-PCR monitoring after third chemotherapy course
Number of subjects: 239
Study 8729953 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐2 6 x 10(6) units/M2 IV three days a week for four weeks
Number of subjects: 84
Study 8729953 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐2 5 x 10(6) units/M2 IV plus B‐IFN 6 x 10(6) units/M2 IV three days a week for four weeks
Number of subjects: 84
Study 8729953 — intervention group
Group type: COMPARATOR
Intervention: IL‐2
Number of subjects: 84
Study 8729953 — intervention group
Group type: COMPARATOR
Intervention: IL‐2 + B‐IFN
Number of subjects: 84
Study 1710823 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 35
Study 1710823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 6110915 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen treatment
Number of subjects: 0
Study 6110915 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin
Number of subjects: 0
Study 30327841 — intervention group
Group type: EXPERIMENTAL
Intervention: iTBCT
Number of subjects: 172
Study 30327841 — intervention group
Group type: COMPARATOR
Intervention: STWU
Number of subjects: 172
Study 30327841 — intervention group
Group type: COMPARATOR
Intervention: iTBCT vs STWU
Number of subjects: 172
Study 28705210 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation of the foot for 60 minutes daily for 3 days after surgery
Number of subjects: 66
Study 28705210 — intervention group
Group type: COMPARATOR
Intervention: Routine postoperative care (Control)
Number of subjects: 66
Study 24977459 — intervention group
Group type: EXPERIMENTAL
Intervention: Ospemifene 60 mg/day
Number of subjects: 2166
Study 24977459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2166
Study 24494292 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing intervention in warm needling moxibustion (observation group)
Number of subjects: 200
Study 24494292 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing in warm needling moxibustion (control group)
Number of subjects: 200
Study 22338959 — intervention group
Group type: EXPERIMENTAL
Intervention: Plantar angle-stable plate
Number of subjects: 12
Study 22338959 — intervention group
Group type: COMPARATOR
Intervention: Dorsomedial angle-stable plate
Number of subjects: 12
Study 20144417 — intervention group
Group type: EXPERIMENTAL
Intervention: ADP-RM short-term risk analysis
Number of subjects: 10
Study 20144417 — intervention group
Group type: EXPERIMENTAL
Intervention: ADP-RM medium-term risk management
Number of subjects: 10
Study 20144417 — intervention group
Group type: EXPERIMENTAL
Intervention: ADP-RM system
Number of subjects: 10
Study 16986228 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg plus HCTZ 25 mg once daily
Number of subjects: 0
Study 16986228 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 10 mg once daily
Number of subjects: 0
Study 14979508 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led outpatient management
Number of subjects: 74
Study 14979508 — intervention group
Group type: COMPARATOR
Intervention: Paediatrician management
Number of subjects: 74
Study 11169534 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 9
Study 11169534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 9024115 — intervention group
Group type: EXPERIMENTAL
Intervention: Early postpartum discharge program with nursing care available by telephone or at home at 34 to 38 weeks' gestation and at < or = 48 hours and at 3, 5, and 10 days post partum
Number of subjects: 175
Study 9024115 — intervention group
Group type: EXPERIMENTAL
Intervention: Early postpartum discharge program
Number of subjects: 175
Study 9024115 — intervention group
Group type: COMPARATOR
Intervention: Standard postpartum care with a stay of 48 to 72 hours
Number of subjects: 175
Study 8329292 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicaprost 5 micrograms
Number of subjects: 8
Study 8329292 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicaprost 7.5 micrograms
Number of subjects: 8
Study 8329292 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicaprost 10 micrograms
Number of subjects: 8
Study 8329292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3012819 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 14
Study 3012819 — intervention group
Group type: EXPERIMENTAL
Intervention: BM 13.177
Number of subjects: 14
Study 3012819 — intervention group
Group type: COMPARATOR
Intervention: Control (both groups)
Number of subjects: 14
Study 30772975 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose group (300 mg clopidogrel)
Number of subjects: 0
Study 30772975 — intervention group
Group type: COMPARATOR
Intervention: Standard dose group (75 mg clopidogrel)
Number of subjects: 0
Study 30772975 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose group (CYP2C19*2 carriers)
Number of subjects: 0
Study 30772975 — intervention group
Group type: COMPARATOR
Intervention: Standard dose group (CYP2C19*2 carriers)
Number of subjects: 0
Study 29995359 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianeptine 25-50 mg/d
Number of subjects: 311
Study 29995359 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 5-10 mg/d
Number of subjects: 311
Study 29995359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 311
Study 26893309 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft tissue treatment (Astym) and eccentric exercise
Number of subjects: 16
Study 26893309 — intervention group
Group type: COMPARATOR
Intervention: Eccentric exercise only
Number of subjects: 16
Study 24796199 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-segment pedicle screw instrumentation with bone grafting and pedicle screw implanting in injured vertebra (Group A)
Number of subjects: 40
Study 24796199 — intervention group
Group type: COMPARATOR
Intervention: Cross segment pedicle instrumentation with bone grafting in injured vertebra (Group B)
Number of subjects: 40
Study 24796199 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 24796199 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-segment pedicle screw instrumentation (Group A)
Number of subjects: 40
Study 24796199 — intervention group
Group type: COMPARATOR
Intervention: Cross segment pedicle instrumentation (Group B)
Number of subjects: 40
Study 23100429 — intervention group
Group type: EXPERIMENTAL
Intervention: First context manipulation with U-shaped object
Number of subjects: 0
Study 23100429 — intervention group
Group type: EXPERIMENTAL
Intervention: Second context manipulation with U-shaped object
Number of subjects: 0
Study 23100429 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudorandom sequence of context switches with U-shaped object
Number of subjects: 0
Study 19875236 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous pedicle island flap
Number of subjects: 40
Study 19875236 — intervention group
Group type: COMPARATOR
Intervention: Superficial temporal artery island flap
Number of subjects: 40
Study 17385968 — intervention group
Group type: EXPERIMENTAL
Intervention: Common cold prime
Number of subjects: 0
Study 17385968 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular disease prime
Number of subjects: 0
Study 17385968 — intervention group
Group type: COMPARATOR
Intervention: Neutral shopping prime
Number of subjects: 0
Study 15750362 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong lessons for 20 minutes at least twice weekly over a period of 6 months
Number of subjects: 90
Study 15750362 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 90
Study 12150309 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose warfarin
Number of subjects: 296
Study 12150309 — intervention group
Group type: COMPARATOR
Intervention: Adjusted-dose warfarin
Number of subjects: 296
Study 10215274 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior aspirin use
Number of subjects: 9461
Study 10215274 — intervention group
Group type: COMPARATOR
Intervention: Eptifibatide
Number of subjects: 9461
Study 8530644 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotrophin-releasing hormone agonist (GnRHa, triptorelin) 0.1 mg s.c. injection
Number of subjects: 48
Study 8530644 — intervention group
Group type: COMPARATOR
Intervention: Human chorionic gonadotrophin (HCG) 10,000 IU i.m. injection
Number of subjects: 48
Study 2115755 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive postfall assessment (n = 79)
Number of subjects: 160
Study 2115755 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 81)
Number of subjects: 160
Study 320109 — intervention group
Group type: EXPERIMENTAL
Intervention: D-penicillamine (1-2 g daily)
Number of subjects: 35
Study 320109 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (15 mg daily)
Number of subjects: 35
Study 320109 — intervention group
Group type: EXPERIMENTAL
Intervention: D-penicillamine
Number of subjects: 35
Study 320109 — intervention group
Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 35
Study 31159884 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 39
Study 31159884 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study 27745532 — intervention group
Group type: EXPERIMENTAL
Intervention: HUD‐VASH (housing subsidies and case management)
Number of subjects: 460
Study 27745532 — intervention group
Group type: COMPARATOR
Intervention: Case management only
Number of subjects: 460
Study 27745532 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 460
Study 26669544 — intervention group
Group type: COMPARATOR
Intervention: External Connection (EC) implants
Number of subjects: 200
Study 26669544 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal Connection (IC) implants
Number of subjects: 200
Study 23115085 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of rifampicin (600 mg)
Number of subjects: 0
Study 23115085 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of rifampicin (600 mg)
Number of subjects: 0
Study 23115085 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin
Number of subjects: 0
Study 21787052 — intervention group
Group type: EXPERIMENTAL
Intervention: Helping to Overcome PTSD through Empowerment (HOPE)
Number of subjects: 70
Study 21787052 — intervention group
Group type: COMPARATOR
Intervention: Standard Shelter Services (SSS)
Number of subjects: 70
Study 18258749 — intervention group
Group type: EXPERIMENTAL
Intervention: Licabazepine 500 mg single dose
Number of subjects: 24
Study 18258749 — intervention group
Group type: EXPERIMENTAL
Intervention: Licabazepine 500 mg multiple doses (500 mg bid on days 3 to 6)
Number of subjects: 24
Study 18258749 — intervention group
Group type: COMPARATOR
Intervention: Licabazepine 500 mg single dose under fasted conditions
Number of subjects: 24
Study 18258749 — intervention group
Group type: COMPARATOR
Intervention: Licabazepine 500 mg single dose under fed conditions
Number of subjects: 24
Study 16239861 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral therapy (GCBT) for 12 weeks
Number of subjects: 40
Study 16239861 — intervention group
Group type: COMPARATOR
Intervention: Sertraline for 12 weeks
Number of subjects: 40
Study 12407614 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amiodarone, 15 mg/kg, 4 hours after arrival in the intensive care unit, followed by 7 mg/kg/d until hospital discharge
Number of subjects: 200
Study 12407614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 12407614 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amiodarone
Number of subjects: 200
Study 12407614 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amiodarone and Placebo
Number of subjects: 200
Study 9924052 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch for 5 months with nicotine nasal spray for 1 year
Number of subjects: 237
Study 9924052 — intervention group
Group type: COMPARATOR
Intervention: Nicotine patch with placebo spray
Number of subjects: 237
Study 7760092 — intervention group
Group type: EXPERIMENTAL
Intervention: Bispectral Index (BIS)
Number of subjects: 42
Study 7760092 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative Delta Power
Number of subjects: 42
Study 7760092 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS at 1.25 MAC isoflurane
Number of subjects: 42
Study 7760092 — intervention group
Group type: COMPARATOR
Intervention: Other EEG variables
Number of subjects: 42
Study 2194901 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopic guidance
Number of subjects: 43
Study 2194901 — intervention group
Group type: COMPARATOR
Intervention: Blinded technique
Number of subjects: 43
Study 7226565 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (4 mg intravenous)
Number of subjects: 10
Study 7226565 — intervention group
Group type: COMPARATOR
Intervention: Standardized exercise tests without naloxone
Number of subjects: 10
Study 31393378 — intervention group
Group type: EXPERIMENTAL
Intervention: elvitegravir (EVG)
Number of subjects: 323
Study 31393378 — intervention group
Group type: EXPERIMENTAL
Intervention: dolutegravir (DTG)
Number of subjects: 323
Study 31393378 — intervention group
Group type: EXPERIMENTAL
Intervention: raltegravir (RAL)
Number of subjects: 323
Study 31393378 — intervention group
Group type: COMPARATOR
Intervention: first-line group
Number of subjects: 323
Study 31393378 — intervention group
Group type: COMPARATOR
Intervention: switch group
Number of subjects: 323
Study 31393378 — intervention group
Group type: EXPERIMENTAL
Intervention: dolutegravir (DTG) in switch group
Number of subjects: 323
Study 31393378 — intervention group
Group type: EXPERIMENTAL
Intervention: elvitegravir (EVG) in switch group
Number of subjects: 323
Study 31393378 — intervention group
Group type: EXPERIMENTAL
Intervention: raltegravir (RAL) in switch group
Number of subjects: 323
Study 27106901 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training programme
Number of subjects: 321
Study 27106901 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 321
Study 25945826 — intervention group
Group type: EXPERIMENTAL
Intervention: System A
Number of subjects: 79
Study 25945826 — intervention group
Group type: COMPARATOR
Intervention: System B
Number of subjects: 79
Study 25945826 — intervention group
Group type: EXPERIMENTAL
Intervention: Both systems
Number of subjects: 79
Study 23764566 — intervention group
Group type: EXPERIMENTAL
Intervention: MMT + AA (methadone maintenance treatment plus auricular acupuncture)
Number of subjects: 69
Study 23764566 — intervention group
Group type: COMPARATOR
Intervention: MMT (methadone maintenance treatment)
Number of subjects: 69
Study 21811051 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg α‐lipoic acid (ALA) per day
Number of subjects: 467
Study 21811051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 467
Study 18596668 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 117
Study 16926119 — intervention group
Group type: EXPERIMENTAL
Intervention: mini‐BCP supplemented with potassium (initial/others: 15.4/9.8 mEq/L) and magnesium (initial/others: 6.5/4.0 mEq/L)
Number of subjects: 30
Study 16926119 — intervention group
Group type: COMPARATOR
Intervention: 4:1‐diluted BCP modified with Buckberg solution
Number of subjects: 30
Study 16306500 — intervention group
Group type: EXPERIMENTAL
Intervention: Squash specific graded test (ST)
Number of subjects: 7
Study 16306500 — intervention group
Group type: COMPARATOR
Intervention: Incremental treadmill test (TT)
Number of subjects: 7
Study 11887513 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime & Bond NT + Surefil
Number of subjects: 20
Study 11887513 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime & Bond NT + Dyract Flow + Surefil
Number of subjects: 20
Study 11887513 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime & Bond NT + Flow-it + Surefil
Number of subjects: 20
Study 11887513 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime & Bond NT + Dyract AP + Surefil
Number of subjects: 20
Study 11887513 — intervention group
Group type: COMPARATOR
Intervention: Fuji II LC + Prime & Bond NT + Surefil
Number of subjects: 20
Study 10449027 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-leg Wingate Test (SLWAnT) with constant braking force
Number of subjects: 20
Study 10449027 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-leg Wingate Test (SLWAnT) with varying braking force
Number of subjects: 20
Study 7598243 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg
Number of subjects: 360
Study 7598243 — intervention group
Group type: EXPERIMENTAL
Intervention: droperidol 1.25 mg
Number of subjects: 360
Study 7598243 — intervention group
Group type: EXPERIMENTAL
Intervention: perphenazine 5 mg
Number of subjects: 360